Iovance Biotherapeutics reported its Q1 2024 earnings yesterday. The company made a net loss of $(113m), or $(0.42) per share. Iovance secured a historic approval for a first solid tumor targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results